BiologicalDrug
Etilagimod alpha clinical trials
Also written IMP321 and eftilagimod alfa.
- studies test it
- 13
- open now
- 1
- in phase 3
- 2
- first study started
- 2005
Keep track of what changes. Save the etilagimod alpha studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2005 (3)
| Year | Studies |
|---|---|
| 2005 | 3 |
| 2006 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 3 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 6
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 2
Immutep S.A.S. (10) · Maria Sklodowska-Curie National Research Institute of Oncology (1) · Immutep Australia Pty. Ltd. (1) · George Washington University (1)
Often tested with
Tested in the same studies.
Pembrolizumab (3) · Hepatitis B Antigens (1) · Hepatitis B Surface Antigens (1) · Paclitaxel (1)
Studies
Open first, then newest update. How each study uses etilagimod alpha is read from its arms, and is right about nine times in ten.
Testing it · 13
- Efti in Patients With Hormone Receptor Positive/HER2-neg Breast CancerNot yet recruitingPhase 2George Washington UniversityNCT07102940Written as Eftilagimod Alfa (Efti)
- Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel ChemotherapyTerminatedPhase 2/3Immutep S.A.S.NCT05747794Written as eftilagimod alpha
- Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCCCompletedPhase 2Immutep S.A.S.NCT03625323Written as eftilagimod alpha
- Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)Active, not recruitingPhase 3Immutep S.A.S.NCT06726265Written as eftilagimod alfa
- Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCCCompletedPhase 2Immutep S.A.S.NCT04811027Written as eftilagimod alpha
- Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO TrialActive, not recruitingPhase 2Maria Sklodowska-Curie National Research Institute of OncologyNCT06128863Written as Pembrolizumab, Eftilagimod alfa
- A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of PaclitaxelWithdrawnPhase 1Immutep S.A.S.NCT04252768Written as Eftilagimod Alpha
- IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast CarcinomaCompletedPhase 2Immutep S.A.S.NCT02614833Written as IMP321 (eftilagimod alpha)
- Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic MelanomaCompletedPhase 1Immutep Australia Pty. Ltd.NCT02676869Written as IMP321 (eftilagimod alpha)
- IMP321 Plus First-line Paclitaxel in Metastatic Breast CarcinomaCompletedPhase 1Immutep S.A.S.NCT00349934Written as IMP321
- IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)CompletedPhase 1Immutep S.A.S.NCT00351949Written as IMP321
- A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321CompletedPhase 1Immutep S.A.S.NCT00354861Written as hepatitis B antigen (without alum) plus IMP321
- Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu AntigenCompletedPhase 1Immutep S.A.S.NCT00354263Written as IMP321
Given in every arm · 2 — etilagimod alpha is usual care beside what is tested
- Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid TumorsActive, not recruitingPhase 1Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT03252938Written as IMP321
- Immunization of Disease-Free Melanoma Patients With Different HLA-A2 PeptidesTerminatedPhase 1/2Cliniques universitaires Saint-Luc- Université Catholique de LouvainNCT00365937Written as IMP321
Codes
What other systems call etilagimod alpha · ClinicalTrials.gg INT001746
- UNII (FDA) SJ82PK3HWAEFTILAGIMOD ALFAConfirmed FDA, Wikidata
- Wikidata Q25326850etilagimod alphaConfirmed FDA, Wikidata
- DrugBank DB16150One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | SJ82PK3HWA | EFTILAGIMOD ALFA | Confirmed FDA, Wikidata |
| Wikidata | Q25326850 | etilagimod alpha | Confirmed FDA, Wikidata |
| DrugBank | DB16150 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.